$3.26-0.10 (-2.98%)
Aclarion, Inc.
Aclarion, Inc. in the Healthcare sector is trading at $3.26. Wall Street consensus targets $7.50 (1 analysts), implying a +130.1% move over the next 12 months. The stock is currently near its 52-week low of $2.34, remaining 36.0% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Aclarion, Inc. operates as a healthcare technology company in the United States. It uses magnetic resonance spectroscopy (MRS) combined with proprietary signal-processing biomarkers to optimize clinical treatments. The company develops NOCISCAN, whic...
Aclarion (ACON) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Aclarion (ACON) delivered earnings and revenue surprises of +13.55% and -29.53%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Natera (NTRA) delivered earnings and revenue surprises of -5.26% and +13.26%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Aclarion ( NASDAQ:ACON ) Second Quarter 2025 Results Key Financial Results Net loss: US$1.60m (loss widened by 29% from...